| Abacavir–lamivudine versus tenofovir–emtricitabine for initial HIV-1 therapy PE Sax, C Tierney, AC Collier, MA Fischl, K Mollan, L Peeples, C Godfrey, ... New England Journal of Medicine 361 (23), 2230-2240, 2009 | 413 | 2009 |
| Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial ES Daar, C Tierney, MA Fischl, PE Sax, K Mollan, C Budhathoki, ... Annals of internal medicine 154 (7), 445-456, 2011 | 388 | 2011 |
| Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data KR Mollan, M Smurzynski, JJ Eron, ES Daar, TB Campbell, PE Sax, ... Annals of internal medicine 161 (1), 1-10, 2014 | 241 | 2014 |
| A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus WA Fischer, JJ Eron Jr, W Holman, MS Cohen, L Fang, LJ Szewczyk, ... Science translational medicine 14 (628), eabl7430, 2021 | 228 | 2021 |
| Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results PE Sax, C Tierney, AC Collier, ES Daar, K Mollan, C Budhathoki, ... Journal of Infectious Diseases 204 (8), 1191-1201, 2011 | 225 | 2011 |
| Molnupiravir, an oral antiviral treatment for COVID-19 W Fischer, JJ Eron Jr, W Holman, MS Cohen, L Fang, LJ Szewczyk, ... MedRxiv, 2021.06. 17.21258639, 2021 | 212 | 2021 |
| Crowdsourcing HIV test promotion videos: a noninferiority randomized controlled trial in China W Tang, L Han, J Best, Y Zhang, K Mollan, J Kim, F Liu, M Hudgens, ... Clinical infectious diseases 62 (11), 1436-1442, 2016 | 130 | 2016 |
| Crowdsourcing to expand HIV testing among men who have sex with men in China: a closed cohort stepped wedge cluster randomized controlled trial W Tang, C Wei, B Cao, D Wu, KT Li, H Lu, W Ma, D Kang, H Li, M Liao, ... PLoS medicine 15 (8), e1002645, 2018 | 121 | 2018 |
| Generalizing evidence from randomized trials using inverse probability of sampling weights AL Buchanan, MG Hudgens, SR Cole, KR Mollan, PE Sax, ES Daar, ... Journal of the Royal Statistical Society Series A: Statistics in Society 181 …, 2018 | 115 | 2018 |
| A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and … WC Miller, IF Hoffman, BS Hanscom, TV Ha, K Dumchev, Z Djoerban, ... The Lancet 392 (10149), 747-759, 2018 | 87 | 2018 |
| The differential short-and long-term effects of HIV-1 latency-reversing agents on T cell function G Clutton, Y Xu, PL Baldoni, KR Mollan, J Kirchherr, W Newhard, K Cox, ... Scientific reports 6 (1), 30749, 2016 | 81 | 2016 |
| Ultra-long-acting removable drug delivery system for HIV treatment and prevention M Kovarova, SR Benhabbour, I Massud, RA Spagnuolo, B Skinner, ... Nature communications 9 (1), 4156, 2018 | 73 | 2018 |
| Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes TJ Wilkin, JE McKinnon, AG DiRienzo, K Mollan, CV Fletcher, ... The Journal of infectious diseases 199 (6), 866-871, 2009 | 68 | 2009 |
| Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention MR Nicol, Y Fedoriw, M Mathews, HMA Prince, KB Patterson, E Geller, ... The Journal of Clinical Pharmacology 54 (5), 574-583, 2014 | 56 | 2014 |
| Incident HIV among pregnant and breastfeeding women in sub-Saharan Africa: a systematic review and meta-analysis LA Graybill, M Kasaro, K Freeborn, JS Walker, C Poole, KA Powers, ... AIDS (London, England) 34 (5), 761, 2020 | 53 | 2020 |
| Disclosure of sexual orientation to health professionals in China: results from an online cross‐sectional study W Tang, J Mao, S Tang, C Liu, K Mollan, B Cao, T Wong, Y Zhang, ... Journal of the International AIDS Society 20 (1), 21416, 2017 | 53 | 2017 |
| Benefits and potential harms of HIV self-testing among men who have sex with men in China: an implementation perspective Y Qin, W Tang, A Nowacki, K Mollan, SA Reifeis, MG Hudgens, NS Wong, ... Sexually transmitted diseases 44 (4), 233, 2017 | 45 | 2017 |
| Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine KY Smith, C Tierney, K Mollan, CS Venuto, C Budhathoki, Q Ma, ... Clinical infectious diseases 58 (4), 555-563, 2014 | 39 | 2014 |
| The interplay between immune maturation, age, chronic viral infection and environment KL Oxford, MGA dela Pena-Ponce, K Jensen, MK Eberhardt, A Spinner, ... Immunity & Ageing 12, 1-20, 2015 | 33 | 2015 |
| Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection CB Jabara, F Hu, KR Mollan, SE Williford, P Menezes, Y Yang, JJ Eron, ... Antimicrobial agents and chemotherapy 58 (10), 6079-6092, 2014 | 33 | 2014 |
Michael G HudgensProfessor of Biostatistics, University of North CarolinaVerified email at bios.unc.edu
